The European startup GenSight will start a clinical trial in the UK to restore sight in patients with retinitis pigmentosa, the website labiotech.eu reports.
The UK Medicines and Healthcare Regulatory Agency (MHRA) has accepted GenSight’s application to run a clinical trial in the UK testing the therapy, which has the potential to treat all forms of retinitis pigmentosa. The genetic disease causes progressive vision loss, usually leading to blindness by age 40.
The Phase I/II trial, called PIONEER, will study the safety and tolerability of GenSight’s therapy, called GS030.
Read the full story: